XIAMEN, FUJIAN, CHINA, December 19, 2025 / EINPresswire.com / -- The global landscape of functional ingredients is being reshaped by an accelerating consumer focus on healthspan, proactive nutrition, and ingredient transparency. Amidst this dynamism, collagen and gelatin have transitioned from niche food stabilizers into cornerstone ingredients for pharmaceutical, nutraceutical, and food and beverage applications. To lead in this environment requires more than capacity; it demands certified qual

XIAMEN, FUJIAN, CHINA, December 19, 2025 / EINPresswire.com / -- A gourmet pastry chef requires precise gelling capabilities for a delicate mousse, demanding leaf gelatin that dissolves cleanly without residue. Simultaneously, a leading nutraceutical company needs consistent bloom and purity in its gelatin powder to ensure its capsule shells meet pharmacopeial standards. The success of both operations, across high-end culinary arts and stringent pharmaceutical applications, relies entirely on a

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstancesREYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of T

Guerbet announces the appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee Villepinte, December 19, 2025: GUERBET (FR0000032526 GBT), a global player in medical imaging, announces the appointment of François Convenant as Senior Vice President of Interventional Radiology.In this role, he joins the Guerbet Group's Executive Committee (COMEX). This appointment marks an important milestone for Guerbet, confirming i

Staar Surgical, a manufacturer of the Implantable Collamer Lens, has delayed a shareholder vote on Alcon’s planned $1.6 billion takeover offer for the fourth time since October. In October, the vote was delayed until November 6, and was then pushed to December 3. The new vote is scheduled for January 6. Broadwood Partners, which holds 30.2% of Staar’s common shares, has advocated against the sale since the beginning, arguing that the deal undervalues the business and reflects a flawed sales proc

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. PROPHASE LABS (NASDAQ:PRPH) ABL will gain enhanced access to U.S. capital markets and accelerate commercialization in the U.S. ABL’s international distribution network will support global expansion of ProPhase’s portfolio” — Dr Chalom B. Sayada LUXEMBOURG VILLE, LUXEMBOURG, December 19, 2025 / EINPresswire.com / -- Advanced Biological Laborator

PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo, as a result the study will be closed. The investigational medicinal product (fidrisertib) was generally well tolerated, with no safety concerns in the trial. “These results are disappointing for the FOP c

BioMarin Pharmaceutical agreed to buy Amicus Therapeutics for $14.50 per share in cash, or approximately $4.8 billion, adding treatments for Fabry and Pompe to its rare disease portfolio. The deal, announced Friday, represents a 33% premium to Amicus' closing share price on Dec. 18 and has been approved by the boards of both companies. "Immediately upon close, this transaction is expected to accelerate BioMarin's revenue growth and strengthen our financial outlook," remarked CEO Alexander Hardy.

China appears to be outpacing the US in parts of biopharmaceutical innovation more quickly than previously understood, according to a new paper released Friday by the National Security Commission on Emerging Biotechnology (NSCEB).The analysis sharpens warnings first issued in April, when the commission concluded US policymakers had a three-year window to retain, or in some cases regain, leadership in biotechnology before risking long-term economic, military and technological disadvantages. That

Altimmune said Friday that its experimental drug pemvidutide continued to improve key non-invasive markers of fibrosis through 48 weeks in a mid-stage trial of patients with metabolic dysfunction-associated steatohepatitis (MASH), extending signals first seen at six months and clearing the way for Phase III testing next year.The Phase IIb IMPACT trial randomised 212 patients with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes to receive either a 1.2 mg or 1.8 mg weekly